LumiThera
LumiThera develops and manufactures the Valeda Light Delivery System, a photobiomodulation (PBM) medical device designed to treat early and intermediate dry age-related macular degeneration (dry AMD). The company's proprietary technology uses multiwavelength LEDs (590 nm yellow, 660 nm red, and 850 nm near-infrared) to stimulate retinal cells and slow disease progression. The Valeda system received FDA authorization in November 2024, making it the first non-invasive FDA-approved treatment for dry AMD.
Acquired
LumiThera has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Employees
42–45
Total Funding
$29.5M
5 rounds
Funding
Total raised $29.5M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series D
Date
May 8, 2024
Amount
$10M
Valuation
—
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 8, 2024 | Series D | $10M | — | |
| January 13, 2020 | Series C | $14M | — | WaterStar Capital |
| November 23, 2016 | Series B | $5.5M | — |
Prominent Investors
Leadership
Clark E. Tedford
President & CEO, Co-Founder
Robert Dotson
Co-Founder
James Carroll
Co-Founder
Graham Merry
Co-Founder
Luis De Taboada
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Apellis Pharmaceuticals
Develops complement-targeted therapies for dry AMD including pegcetacoplan (Fabhalta)
Genentech/Roche
Developing faricimab (Vabysmo) for dry AMD treatment
Iveric Bio
Focused on inherited retinal diseases and age-related retinal degeneration therapies
Optos (Natus Medical)
Provides retinal imaging and diagnostic devices for ophthalmology
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.